Prognostic factors and staging in multiple myeloma
Rafael Fonseca1, Jesus San Miguel
1Mayo Clinic Arizona, 13208 East Shea Boulevard, Collaborative Research Building, 3-006, Scottsdale, AZ 85259-5494, USA. fonseca.rafael@mayo.edu
Hematology/Oncology Clinics of North America
|November 13, 2007
Summary
Accurate multiple myeloma prognostication relies on both host and cellular factors. Comprehensive molecular cytogenetic assessment at diagnosis, alongside conventional markers, is recommended for improved clinical outcome prediction.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Multiple myeloma prognostication utilizes independent predictors to determine clinical outcomes.
- Prognosis is influenced by host factors and intrinsic cellular factors.
Purpose of the Study:
- To highlight the importance of host and cellular factors in multiple myeloma prognosis.
- To recommend essential prognostic assessments at the time of diagnosis.
Main Methods:
- Review of existing studies on multiple myeloma prognostication.
- Emphasis on molecular cytogenetic assessment, beta2-microglobulin, albumin levels, and plasma cell proliferative activity.
Main Results:
- Host factors are more relevant shortly after diagnosis, while cellular factors become predominant over time.
- A combination of molecular cytogenetics and conventional markers provides a comprehensive prognostic evaluation.
Conclusions:
- Recommend comprehensive molecular cytogenetic assessment, beta2-microglobulin, albumin, and proliferative activity for initial prognostication.
- Advocate for the integration of novel prognostication methods in clinical trials for multiple myeloma.
